August 2, 2022
Astellas Pharma suffered external factors such as the yen’s plunge and the Russia-Ukraine war in first-quarter earnings, with its operating and net profit shriveling 8.2% and 19.1%, respectively. On a core basis, however, operating profit was virtually flat versus a...read more